Related Experiment Video

Updated: Apr 5, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

920

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer

Gorjan Hrustanovic1,2, Victor Olivas1,2, Evangelos Pazarentzos1,2

  • 1Department of Medicine, University of California at San Francisco, San Francisco, California, USA.

Nature Medicine
|August 25, 2015
PubMed

Insights

Targeting the RAS-mitogen-activated protein kinase (MAPK) pathway alongside ALK inhibitors can overcome drug resistance in EML4-ALK lung adenocarcinoma. This combination therapy improves treatment response and duration, offering a new strategy for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer drug resistance remains a major challenge in treating lung adenocarcinoma.
  • The anaplastic lymphoma kinase (ALK) fusion protein is a key driver in a subset of lung cancers.
  • Understanding resistance mechanisms is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of the RAS-RAS-mitogen-activated protein kinase (MAPK) pathway in EML4-ALK lung adenocarcinoma survival and resistance.
  • To evaluate the efficacy of upfront combination therapy targeting both ALK and MEK.

Main Methods:

  • Utilized preclinical models of lung adenocarcinoma with EML4-ALK fusion.
  • Analyzed RAS-MAPK pathway activation and its role in tumor cell survival.
  • Assessed resistance mechanisms including KRAS amplification and DUSP6 downregulation.
  • Investigated the effect of combined ALK and MEK inhibition.

Main Results:

  • RAS-MAPK pathway, not other ALK effectors, is essential for EML4-ALK lung cancer cell survival.
  • EML4-ALK activates RAS-MAPK signaling through all three RAS isoforms.
  • KRAS amplification or DUSP6 downregulation leads to resistance against ALK inhibitors.
  • Combined ALK and MEK inhibition significantly improved response magnitude and duration in preclinical models.

Conclusions:

  • RAS-MAPK pathway dependence is a hallmark of EML4-ALK lung adenocarcinoma.
  • Upfront combination therapy with ALK and MEK inhibitors is a promising strategy to overcome drug resistance.
  • This approach has the potential to improve patient outcomes in EML4-ALK-positive lung adenocarcinoma.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K